Skip to content
NBDC Human Database

No datasets in the cart.

Go to the cart

Due to system maintenance, the application system, application review by the Data Access Committee will be unavailable during the following period.
Schedule: October 5th (Mon), 2026, 9:00 - October 7th (Wed), 2026, 15:00 (JST)
We apologize for any inconvenience this may cause and appreciate your understanding.

We are currently receiving a large number of applications for data submission, and the review process is taking longer than usual.We sincerely apologize for the delay and kindly ask for your understanding. When submitting an application, we would greatly appreciate it if you could allow sufficient time for the processing.

Following a change to our organizational structure effective April 1, 2026, this division has been renamed from the "Database Center for Life Science, Joint Support-Center for Data Science Research" to the "Database Division for Life Science (DBCLS), BioData Science Initiative (BSI), National Institute of Genetics (NIG)". Where the former name still appears in the guidelines, please read it as the new name.

Research ID

hum0317-v3Release info

Latest

Research title

Research on the establishment of patient derived xenograft models useful for drug discovery research

Research overview

Aims
To analyze the pharmacokinetics and therapeutic effects of anticancer drugs in patients with cancer who are undergoing or have already begun surgical resection, radiotherapy, or anticancer drug therapy by creating a patient-derived xenograft (PDX) model using patient specimens to approximate human biological tissues. This is to create a PDX model using patient specimens to analyze the pharmacokinetics and therapeutic effects of anticancer drugs in a manner that approximates human tissues.
Methods
Whole-exome sequencing and RNA-sequencing analyses
Participants/materials
- Non-small cell lung cancer with driver gene abnormalities 4 cases (33 samples)
- 52 + 269 cases with any cancer (germline tissues:44 + 269 samples, tumor tissues from PDX: 52 + 795 samples, tumor tissues from patients: 125 samples)
URL

Datasets

CartDataset IDType of dataAnalysis methodAccess criteriaDate published
JGAD000530NGS (Exome, RNA-seq)
  • WES
  • RNA-seq
Controlled-access (Type I)2021-12-07
JGAD000840NGS (Exome, RNA-seq)
  • WES
  • RNA-seq
Controlled-access (Type I)2024-06-11
JGAD000995NGS (Exome)
  • WES
Controlled-access (Type I)2025-11-19

Data provider

Principal investigator
Akinobu Hamada
Affiliation
Division of Molecular Pharmacology, National Cancer Center Research Institute

Research projects

Grants

NameTitleProject number
Cyclic Innovation for Clinical Empowerment (CiCLE), Japan Agency for Medical Research and Development (AMED)
Project to develop a PDX library derived from Japanese cancer patients for the promotion of cancer treatment
  • JP17pc0101011
National Cancer Center Research and Development Fund
Development of a method to establish PDX that correctly reflects the diversity within human tumors
  • 31-A-3
Research on Regulatory Science of Pharmaceuticals and Medical Devices, Japan Agency for Medical Research and Development (AMED)
Study on standardization of non-clinical studies using PDX model
  • JP21mk0101181
KAKENHI Grant-in-Aid for Early-Career Scientists
Establishment of PDX model for non-small cell lung cancer with genetic alteration and basic research for new drug development
  • 18K15296
Cyclic Innovation for Clinical Empowerment (CiCLE), Japan Agency for Medical Research and Development (AMED)
Study on methods for drug discovery research to accelerate the development of anticancer drugs for rare and refractory cancers
  • JP20pc0101051
Research and development program leading genomic research to drug discovery and genomic medicine, Japan Agency for Medical Research and Development (AMED)
Development of an Artificial Intelligence-based system to accelerate drug discovery and research for new anti-cancer agents
  • JP23tk0124004
Practical Research for Innovative Cancer Control, Japan Agency for Medical Research and Development (AMED)
Research on Establishing a Consistent Management Scheme from Cancer Pathogenesis Elucidation to Innovative Medical Practical Application
  • JP23ck0106771

Related publications

TitleDOIDataset ID
Comparative study on the efficacy and exposure of molecular target agents in non-small cell lung cancer PDX models with driver genetic alterations
https://doi.org/10.1158/1535-7163.MCT-21-0371 (opens in a new tab)
A molecular glue RBM39-degrader induces synthetic lethality in cancer cells with homologous recombination repair deficiency
https://doi.org/10.1038/s41698-024-00610-0 (opens in a new tab)
Comprehensive DNA Profiling Strategy for Patient-Derived Xenograft Model Authentication in the J-PDX Library
https://doi.org/10.1038/s41598-025-21299-6 (opens in a new tab)

Controlled access users

Principal investigatorAffiliationCountry/RegionResearch titlePeriod of data useDataset ID
Hirofumi NakaokaDepartment of Cancer Genome Research, Sasaki InstituteJapanGenetic analysis of lung cancer2022-08-17 – 2026-07-23
Michiaki HamadaHamada Laboratory, Faculty of Science and Engineering, Waseda UniversityJapanConstruction of RNA-targeted Drug Discovery Database2023-01-05 – 2027-10-31